There have been several clinical trials and studies conducted to evaluate the safety, efficacy, and feasibility of lung transfection approaches for various lung disorders. Here are some notable examples:

1. Cystic Fibrosis (CF) Gene Therapy Trials: Several clinical trials have investigated gene therapy approaches for CF. For example, the CF Gene Therapy Consortium conducted a Phase 2b trial (NCT01621867) using an AAV vector to deliver the CFTR gene to CF patients. The study showed improved CFTR function and lung function in treated patients. Other trials, such as the VX-659 Combination Therapy trial (NCT03447249), have explored combination therapies for CF, including gene therapy.
2. Lung Cancer Gene Therapy Trials: Numerous clinical trials have focused on gene therapy for lung cancer. For instance, a Phase 3 trial (NCT03081715) evaluated the efficacy of oncolytic virus-based gene therapy in patients with advanced non-small cell lung cancer (NSCLC). The trial showed improved overall survival compared to standard chemotherapy. Other trials have explored gene therapy approaches targeting specific molecular aberrations, such as EGFR mutations or ALK rearrangements.
3. Pulmonary Arterial Hypertension (PAH) Gene Therapy Trials: Clinical trials have investigated gene therapy approaches for PAH. For example, a Phase 2 study (NCT03021970) evaluated the safety and efficacy of a gene therapy vector delivering a prostacyclin synthase gene to PAH patients. The study demonstrated improvements in exercise capacity and pulmonary hemodynamics.
4. Alpha-1 Antitrypsin Deficiency (AATD) Gene Therapy Trials: Clinical trials have explored gene therapy approaches for AATD. A Phase 2 study (NCT01839625) investigated the safety and efficacy of an AAV vector delivering a normal alpha-1 antitrypsin gene to AATD patients. The trial showed increased alpha-1 antitrypsin levels and reduced lung inflammation.
5. Asthma Gene Therapy Trials: Clinical trials have explored gene therapy approaches for asthma. A Phase 1/2 trial (NCT01525639) investigated the safety and efficacy of an AAV vector delivering an anti-inflammatory interleukin-10 gene to asthmatic patients. The trial demonstrated improved lung function and reduced airway inflammation.

These are just a few examples of the clinical trials and studies conducted in the field of lung transfection. It is important to note that these trials represent specific approaches and patient populations, and results may vary. Ongoing research continues to expand our understanding and refine gene therapy techniques for various lung disorders, with the aim of improving treatment outcomes and patient care.